NCT00553800 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer


Sponsors: Fox Chase Cancer Center Genentech OSI Pharmaceuticals	Phases: Phase II
Indications	Acronym: NSCLC
Carcinoma, Non-Small-Cell Lung
Age Groups: Senior	Gender: Both
Names: Drug: bevacizumab and erlotinib	Enrollment: 33

Additional information about NCT00553800.